NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Arcutis Biotherapeutics, Inc. ARQT
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$372.1M
▲ 123.4% vs FY2024
EPS · FY25
$-0.13
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-9.3%
Net margin · FY25
-4.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 372.1M
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 4 cents on every revenue dollar this year.
Per share
USD -0.13
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-9.3%
Return on equity, FY2025
ROE
Operating margin-3.3%
Net margin-4.3%
Return on assets-4.1%
Each USD of equity lost 9 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+365.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.12B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 433.0M
total assets, end of FY2025
Total assetsUSD 433.0M
EquityUSD 189.5M
CashUSD 42.9M
Gross debtUSD 109.0M
Net debtUSD 66.1M
Current ratio3.17×
Net debt stands at 35% of equity.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.4
0.2
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.0
−0.1
−0.2
−0.3
−0.2
−0.1
−0.0
−0.0
EBITDA $B
−0.0
−0.1
−0.2
−0.3
−0.2
−0.1
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.1
−0.3
−0.3
−0.2
−0.1
−0.0
−0.0
EPS, diluted $
−0.13
−1.16
−3.78
−5.66
−4.18
−3.80
−22.78
−15.53
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
−9.3
−113.8
−175.8
−122.8
−72.6
−132.0
·
·
Shares out B
0.12
0.12
0.10
0.06
0.05
0.04
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
22 of 22
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed